You are here

Exploiting Single Nucleotide Polymorphisms for Extreme Performance

Award Information
Agency: Department of Defense
Branch: Army
Contract: W911NF-20-P-0015
Agency Tracking Number: A19B-008-0052
Amount: $165,350.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: A19B-T008
Solicitation Number: 19.B
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-01-15
Award End Date (Contract End Date): 2020-07-19
Small Business Information
100 Corte Placida
Greenbrae, CA 94904
United States
DUNS: 117098254
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Nicholas Marini
 Chief Executive Officer
 (415) 425-9718
 nickmarini01@gmail.com
Business Contact
 Nicholas Marini
Phone: (415) 425-9718
Email: nickmarini01@gmail.com
Research Institution
 Universtiy of California
 Nicholas Marini Nicholas Marini
 
2150 Shattuck Avenue Room 313
Berkeley, CA 94704
United States

 (415) 425-9718
 Nonprofit college or university
Abstract

Advances in DNA sequencing technology have generated a rapid expansion of human genome information and the revelation of extraordinary individual-level genetic variation. Individual genome sequencing will soon be routine and cost-effective. To exploit this resource to the benefit of warfighters, we propose an approach for identifying and characterizing genetic variants that compromise metabolic efficiency (and ultimately physical and cognitive performance), yet are amenable to nutritional optimization. There are 600+ cofactor-dependent enzymes in the human proteome, and preliminary studies provide ample precedence for the remediation of dysfunctional enzyme variants by straightforward vitamin/mineral supplementation. We describe a technology platform in which all possible enzyme variants are functionally assessed and pre-determined for each enzyme/gene. These datasets will serve to rapidly identify carriers of variant enzymes who can metabolically benefit from cofactor supplementation. In Phase I, the approach will be developed on a single high-value target gene, Cystathionine beta-Synthase, necessary for homocysteine clearance and cardio-respiratory fitness. These studies will facilitate Phase II to query all genes related to homocysteine clearance, and to spur a field trial in which individual genotype and metabolite profile are diagnostic for potential performance enhancement. This pioneering work will render genome sequence an asset to improve health, fitness and readiness.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government